Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors

Viviana Bazan, Cesare Gagliardo, Chiara Brando, Antonio Russo, Massimo Galia, Giuseppe Badalamenti, Daniele Fanale, Lorena Incorvaia, Giorgio Madonia, Giovanni Foti, Antonio Russo, Matteo Santoni, Lidia Rita Corsini, Alessandro Inno, Antonio Russo, Stefania Gori, Ivan Fazio, Giorgio Madonia, Daniele Fanale, Chiara BrandoGiuseppe Badalamenti, Alessandra Cucinella, Alessandra Cucinella, Lidia Rita Corsini

Risultato della ricerca: Articlepeer review

Abstract

The introduction of checkpoint inhibitors (ICIs) in renal cell carcinoma (RCC) treatment landscape, resulted in improvements in overall survival (OS) in metastatic patients. Brain metastases (BMs) are a specific metastatic site of interest representing a predictive factor of poor prognosis. Patients with BMs were usually excluded from prospective clinical trials in the past. Despite recent evidence suggest the efficacy and safety of ICIs, the BMs treatment remains a challenge; the immunotherapy responsiveness seems to be multifactorial and dependent on several factors, such as the genetic intratumor heterogeneity and the immunosuppressive role of the brain tumor microenvironment. This review, starting from the immunological background in RCC BMs, provide an overview of the upcoming evidence from clinical trials, address the issues related to the neuroradiological immunotherapy response evaluation and, with a look to the future, describes how the epigenetic modulation of immune evasion could represent a background for new therapeutic strategies.
Lingua originaleEnglish
pagine (da-a)103390-
Numero di pagine12
RivistaCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume163
Stato di pubblicazionePublished - 2021

All Science Journal Classification (ASJC) codes

  • ???subjectarea.asjc.2700.2720???
  • ???subjectarea.asjc.2700.2730???

Fingerprint

Entra nei temi di ricerca di 'Challenges and advances for the treatment of renal cancer patients with brain metastases: From immunological background to upcoming clinical evidence on immune-checkpoint inhibitors'. Insieme formano una fingerprint unica.

Cita questo